Louis Coury currently serves as the Head of Results Generation, Program Support, and Compliance at Biogen, where he plays a pivotal role in ensuring the integrity and reliability of analytical development, testing, and stability operations. With a robust background in chemical and biological reference standards,...
Louis Coury currently serves as the Head of Results Generation, Program Support, and Compliance at Biogen, where he plays a pivotal role in ensuring the integrity and reliability of analytical development, testing, and stability operations. With a robust background in chemical and biological reference standards, Louis oversees a dynamic lab team that spans two sites and is responsible for generating results from an impressive 60,000 sample submissions annually. His leadership extends to managing general lab operations, including operational excellence (OpEx) and capital expenditure (CapEx) budgeting, business continuity planning, and space optimization, as well as overseeing outsourced asset management services.
One of Louis's key projects involves the meticulous curation and verification of experimental data for global regulatory submissions, a critical function that ensures compliance with CFR Title 21 regulations. His expertise in regulatory submissions, coupled with a strong foundation in HPLC and technology transfer, positions him as a vital asset in Biogen's commitment to advancing biopharmaceuticals. Recognized for his contributions in 2022, Louis is passionate about knowledge management and is an advocate for Six Sigma methodologies, which he integrates into his team's processes to enhance efficiency and quality.
Louis's proficiency in laboratory information management systems (LIMS) further strengthens his capability to streamline operations and maintain rigorous standards in the life sciences sector. His managerial skills and dedication to continuous improvement not only foster a culture of excellence within his team but also contribute significantly to Biogen's mission of transforming the lives of patients through innovative therapies.
